MedTrace Logo

Pethema LAL-RI/2008: Treatment for Patients With Standard Risk Acute Lymphoblastic Leukemia

NCT02036489 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 107

Last updated 2020-03-05

No results posted yet for this study

Summary

Understand the dynamics of elimination of MRD in adult patients with standard-risk LAL treated with a pediatric protocol.

Conditions

  • Acute Lymphobkastic Leukemia

Interventions

DRUG

Vincristine

DRUG

Daunorubicin

DRUG

Prednisone

DRUG

L-asparaginase

DRUG

Ciclophosphamide

DRUG

Metotrexate

DRUG

ARA-C

DRUG

Hidrocortisone

DRUG

Mercaptopurine

DRUG

VP-16

DRUG

Dexametasone

Sponsors & Collaborators

  • PETHEMA Foundation

    lead OTHER

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
15 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-01-31
Primary Completion
2019-12-01
Completion
2019-12-01

Countries

  • Spain

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02036489 on ClinicalTrials.gov